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Abstract
AIM
To analyze cytokine levels and to identify their asso-
ciation with outcome in patients with hepatocellular 
carcinoma (HCC) treated with radiotherapy (RT). 
METHODS
Patients with HCC who were treated with RT were 
eligible for this prospective study. Blood samples were 
collected before and after RT, and serum cytokine 
levels including interleukin (IL)-1, IL-6, IL-8, IL-10, 
IL-12, and tumor necrosis factor-α were analyzed. 
RESULTS
Between 2008 and 2009, 51 patients were enrolled in 
this study. Baseline IL-6 level was high in patients with 
a history of pre-RT treatment. Median survival was 13.9 
mo with alpha-fetoprotein (AFP) as a significant factor (P  
= 0.020). Median failure-free survival (FFS) for infield, 
outfield-intrahepatic and extrahepatic failures were 
23.3, 11.5 and 12.0 mo, respectively. Sex and baseline 
IL-6 level were associated with infield FFS, and baseline 
IL-10 level was correlated with outfield-intrahepatic 
FFS. For extrahepatic FFS, AFP was significant (P  = 
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0.034). Patients with a baseline IL-6 level of ≥ 9.7 
pg/mL showed worse infield FFS (P  = 0.005), and this 
significance was observed only in treatment-non-naïve 
patients (P  = 0.022). 
CONCLUSION
In addition to AFP, cytokines seem useful in predicting 
infield and outfield-intrahepatic failure. Serum cytokines 
could be useful biomarkers for predicting RT outcome 
in HCC.
Key words: Hepatocellular carcinoma; Radiotherapy; 
Cytokine; Interleukin-6
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: A prospective study to identify associations 
between serum cytokine levels and radiotherapy 
(RT) outcomes was performed in 51 patients with 
hepatocellular carcinoma. Baseline serum interleukin 
(IL)-6 levels were higher in patients with treatment 
failure than in those without treatment failure. This 
significant difference was observed only in treatment-
non-naïve patients. To predict RT outcomes, analysis of 
baseline serum IL-6 levels may be helpful.
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INTRODUCTION
The liver is an organ that is enriched with immune 
cells. Chronic inflammation caused by infection with 
hepatitis B or C virus or by steatohepatitis is a risk 
factor for the development of hepatocellular carcinoma 
(HCC). Continued cytokine-induced hepatocyte 
damage followed by hepatocyte regeneration leads 
to HCC development. The involvement of interleukin 
(IL)-1, IL-2, IL-6, IL-10, IL-12, tumor necrosis factor 
(TNF)-α, and transforming growth factor (TGF)-β in 
hepatocarcinogenesis has been reported. As levels 
of these cytokines are more increased in patients 
with HCC than in healthy individuals or patients with 
cirrhosis, they have been studied as biomarkers for the 
detection of HCC[1-5]. 
It has been reported that cytokine levels are 
associated with the radiation response of the tumor. 
In general, elevated pro-inflammatory cytokine levels 
before radiotherapy (RT) correlated with treatment 
resistance and poor treatment outcome in several 
cancers. Radiation-induced pro-inflammatory cytokine 
pathways within tumor cells may help the cells survive 
RT[6]. Recently, the application of RT in the treatment 
of HCC has increased[7]. However, there have been few 
studies on the role of cytokines in the RT response in 
patients with HCC.
Several biomarkers in cancer detection or treat-
ment have been studied. As mentioned, cytokines 
play a role in cancer development and treatment 
response. Cytokine levels in serum or plasma are 
easily accessible and may be useful as biomarkers in 
screening for cancer or predicting outcomes[8]. The 
aim of this study was to analyze serum cytokine levels 
and to identify the significance of serum cytokines in 
treatment outcomes for patients with HCC treated with 
RT.
MATERIALS AND METHODS
This study was conducted prospectively and conformed 
to the ethical guidelines of the Declaration of Helsinki. 
It was approved by the Institutional Review Board at 
Yonsei Severance Hospital (IRB number: 4-2008-2012). 
All patients were enrolled after providing written 
informed consent. The number of patients was calcu-
lated using a one-sample t-test. Based on an expected 
dropout rate of 10%, we planned to enroll 109 patients. 
However, the study was closed early due to poor 
accrual. Ultimately, 51 patients were included in this 
study between September 2008 and October 2009.
RT was performed using 3D conformal RT or 
intensity-modulated RT. Blood samples were collected 
from patients before the start and at completion of the 
RT schedule. We selected serum cytokines, including 
IL-1, IL-6, IL-8, IL-10, IL-12 and TNF-α, for analysis 
that were known to be associated with HCC. Serum 
cytokine levels were measured using Cytokine Bead 
Array kits according to the manufacturer’s instructions 
(BD Biosciences, San Jose, CA, United States) using 
a fluorescence-activated cell sorting (FACS) Verse 
flow cytometer (Becton Dickinson, Franklin Lakes, NJ, 
United States). The baseline level was defined as the 
value before RT.
We classified patterns of failure into three cate-
gories: infield failure, outfield-intrahepatic failure, 
and extrahepatic failure. Infield failure was defined 
as progression of the tumor within the RT field that 
covered the planning target volume. Intrahepatic 
failure was defined as progression of the tumor within 
the liver but outside of the RT field. Extrahepatic failure 
was a distant metastasis in lung, bone, etc. Overall 
survival (OS) and failure-free survival (FFS) were 
calculated from the first date of RT to the date of death 
and disease progression, respectively.
Statistical analysis
The statistical significance of differences in mean 
values according to patient and tumor characteristics 
was determined using Student’s t-test or a one-way 
analysis of variance. Survival rates were evaluated 
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using a Kaplan-Meier analysis, and the correlation 
between FFS and clinical factors or serum cytokine 
level as a continuous variable was analyzed using the 
Cox hazard proportional model. Multivariate analysis 
was performed using the Cox stepwise regression 
model. The cut-off value of IL-6 was obtained from a 
receiver operating characteristic (ROC) curve based on 
the Youden index. Statistical analysis was performed 
using SPSS 20.0 (IBM, Armonk, NY, United States). 
RESULTS
Patient, tumor and treatment characteristics
The median follow-up duration for the entire patient 
population was 13.3 mo (range, 1.6-63.5 mo). 
The patient, tumor and treatment characteristics 
are described in Table 1. The median age was 54 years 
(range, 32-75 years). Most patients (92.2%) were 
diagnosed with International Union Against Cancer 
(UICC) stage Ⅲ or Ⅳ HCC, and half of the patients had 
Barcelona Clinic Liver Cancer (BCLC) stage C disease 
at the time of RT. Twenty-two patients (43.1%) had 
a history of pre-RT treatment and were defined as 
treatment-non-naïve patients. All treatment-non-naïve 
patients received transarterial chemoembolization 
(TACE) or transarterial chemoinfusion before RT. 
Additionally, surgery, radiofrequency ablation, holmium, 
or intra-arterial chemotherapy was performed in 7 
patients. The median serum levels of alpha-fetoprotein 
(AFP) and PIVKA-II were 141.9 IU/mL (range, 1.53-83000 
IU/mL) and 600 mAU/mL (range, 12-2000 mAU/mL), 
respectively. The median total prescribed dose of RT 
was 50.4 Gy (range, 45-64.8 Gy) and median duration 
of RT was 34 d (range, 25-56 d). 
Serum cytokine as a prognostic biomarker
We evaluated the correlation between baseline serum 
cytokine levels and the characteristics of patients 
and tumors (Figure 1). Baseline IL-6 and IL-8 levels 
were found to increase with the UICC stage. When 
comparing stage Ⅱ with stage Ⅳ, there was a significant 
difference in the IL-8 level (P = 0.006), and IL-6 
showed borderline significance (P = 0.051). Treatment-
non-naïve patients showed higher baseline serum IL-6 
levels than treatment-naïve patients (P = 0.028). There 
were no significant differences in serum cytokine levels 
according to sex, BCLC stage, portal vein thrombosis, 
tumor multiplicity, and pre-RT tumor marker level.
Serum cytokine as a predictive biomarker
Forty-five patients (88.2%) died during the follow-
up period. Median OS was 13.9 mo (range, 2.2-63.5 
mo) and 1-year and 2-year survival rates were 56.9% 
and 33.3%, respectively. The AFP level was only a 
significant factor for OS (P = 0.020, RR, 1.001, 95%CI: 
1.000-1.002). There was no correlation between OS 
and baseline serum cytokine level (Table 2).
During the follow-up period, treatment failures 
occurred in 40 patients (79.4%), and infield, outfield-
intrahepatic and extrahepatic failures were observed 
in 19, 31 and 31 patients, respectively. The median 
FFS for infield, outfield-intrahepatic, and extrahepatic 
failures were 23.3, 11.5 and 12.0 mo, respectively. 
The correlation of FFS with tumor characteristics and 
baseline cytokine level was described in Tables 3-5. 
For infield FFS, sex (P < 0.001, RR, 47.505, 95%CI: 
7.384-305.601) and baseline serum IL-6 level (P < 
0.001, RR, 1.019, 95%CI: 1.011-1.028) were statis-
tically significant. Baseline serum IL-10 level was a 
significant factor for outfield-intrahepatic FFS (P = 
0.026, RR, 0.830, 95%CI: 0.705-0.978), and AFP was 
associated with extrahepatic failure (P = 0.034, RR, 
1.001, 95%CI: 1.000-1.003).
The cut-off value of baseline serum IL-6 level for 
infield FFS was 9.735 (Figure 2A; AUC 0.748, P = 
0.003, 95%CI: 0.607-0.888). Patients with a baseline 
serum IL-6 level higher than 9.7 pg/mL showed worse 
infield FFS than those with a baseline serum IL-6 level 
less than 9.7 pg/mL (Figure 2B; P = 0.005). 
As baseline serum IL-6 level significantly differed 
between treatment-non-naïve and treatment-naïve 
patients, we performed a subgroup analysis based on 
pre-RT treatment. The subgroup analysis indicated the 
significant difference in baseline serum IL-6 level was 
observed only in treatment-non-naïve patients (Figure 
2C and D; P = 0.002).
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Table 1  Patient, tumor and treatment characteristics
Characteristic n Percent
Age (yr), median 54 (range, 32-75)
Sex Male 44 86.3
Female   7 13.7
Viral type B 44 86.3
C   4   7.8
NBNC   3   5.9
Child-Pugh class A 49 96.1
B   2   3.9
Modified UICC stage II   4   7.8
III 32 62.7
IV 15 29.5
BCLC stage A 14 27.5
B 12 23.5
C 25 49.0
PVT No 31 60.8
Yes 20 39.2
Multiplicity No 25 49.0
Yes 26 51.0
Tumor size in cm, 
median
8.5 (range, 1.0-19.6)
AFP (IU/mL), median 141.9 (range, 1.53-83000)
PIVKA-II (mAU/mL), 
median
600 (range, 12-2000)
Treatment-naïve Yes 29 56.9
No 22 43.1
Total dose of RT (Gy), 
median
50.4 (range, 45-64.8)
NBNC: Non-B non-C; UICC: International Union Against Cancer; 
BCLC: Barcelona Clinic Liver Cancer; PVT: Portal vein thrombosis; AFP: 
α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; 
RT: Radiotherapy.
Cha H et al . Cytokine analysis for hepatocellular carcinoma
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of severe radiation-induced liver disease during RT 
and until 3 mo after the completion of RT. Grade 3-4 
hematologic toxicities including anemia, neutropenia 
and thrombocytopenia were reported in 6, 12 and 
9 patients, respectively. There were also 3 cases of 
hypoalbuminemia, 8 cases of hyperbilirubinemia, 10 
cases of elevated liver enzymes, and 3 cases of gastro-
intestinal bleeding (> grade 3).
DISCUSSION
In this study, we investigated whether the serum 
levels of six cytokines (IL-1, IL-6, IL-8, IL-10, IL-12 and 
Variation of serum cytokine levels
We also analyzed serum cytokine levels on completion 
of RT (Table 6). After RT, serum IL-10 level had 
increased from 4.19 ± 0.41 to 5.83 ± 0.46 (P = 0.002), 
and serum IL-12 level had decreased from 6.10 ± 1.01 
to 4.10 ± 0.59 (P = 0.018). However, these changes 
were not associated with survival or treatment failure. 
Variations in the serum levels of other cytokines after 
RT were not significant.
Treatment toxicity
The median value of the mean liver dose was 20.3 
Gy (range, 5.7-34.9 Gy), and there were no cases 
Figure 1  Baseline serum cytokine levels according to tumor characteristics. A, C, D, E, F and G: There were no significant differences in serum cytokine levels 
according to sex, BCLC stage, portal vein thrombosis, multiplicity and level of alpha-fetoprotein; B: When comparing stage Ⅱ with stage Ⅳ, interleukin (IL)-8 levels 
showed a significant difference (aP = 0.006) and IL-6 showed a borderline significance (P = 0.051); H: Treatment-non-naïve patients showed higher baseline serum 
IL-6 levels than treatment-naïve patients (aP = 0.028).
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TNF-α) would have clinical significance in patients with 
HCC who were treated with RT. We demonstrated that 
patients with a history of pre-RT treatment showed 
a higher baseline serum IL-6 level than treatment-
naïve patients. A high baseline serum IL-6 level was 
also associated with infield failure. The subgroup 
analysis revealed that baseline serum IL-6 levels were 
associated with infield failure only in treatment-non-
naïve patients. 
IL-6 is a pro-inflammatory cytokine and one of 
Table 2  Univariate and multivariate analyses of clinical factors or cytokines for failure-free survival - overall survival
Univariate Multivariate
P  value RR (95%CI) P  value RR (95%CI)
Sex 0.580 1.276 (0.538-3.027)
Age 0.954 1.001 (0.970-1.033)
Stage 0.861 1.052 (0.600-1.844)
BCLC 0.224 1.252 (0.872-1.799)
Size 0.308 1.037 (0.967-1.113)
PVT 0.132 1.581 (0.871-2.871)
LN metastasis 0.867 1.092 (0.389-3.061)
Multiplicity 0.957 1.016 (0.561-1.841)
AFP 0.020 1.001 (1.000-1.002) 0.020 1.001 (1.000-1.002)
PIVKA-II 0.211 1.022 (0.988-1.056)
Pre-RT treatment 0.693 0.887 (0.487-1.608)
Baseline IL-1 0.262 0.979 (0.942-1.016)
Baseline IL-6 0.692 1.001 (0.996-1.007)
Baseline IL-8 0.770 1.000 (0.998-1.002)
Baseline IL-10 0.909 0.994 (0.890-1.109)
Baseline IL-12 0.449 1.014 (0.978-1.052)
Baseline TNF-α 0.573 0.984 (0.930-1.041)
Age, size, AFP, PIVKA-II, and baseline cytokine levels were analyzed as continuous variables using the Cox hazard ratio model. BCLC: Barcelona 
Clinic Liver Cancer; PVT: Portal vein thrombosis; LN: Lymph node; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: 
Radiotherapy; IL: Interleukin; TNF: Tumor necrosis factor.
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Figure 2  Infield failure-free survival according to cut-off value of baseline serum interleukin-6. A: The cut-off value of interleukin (IL)-6 was obtained from a 
receiver operating characteristic (ROC) curve based on the Youden index (AUC, 0.748, P = 0.003, 95%CI: 1.011-1.028); B: Patients with baseline serum IL-6 level 
higher than 9.7 pg/mL showed worse infield FFS than those with baseline serum IL-6 level lower than 9.7 pg/mL (47.5% vs 100%, P = 0.005); C and D: In subgroup 
analysis, the significant difference of infield FFS was observed only in treatment-non-naïve patients (P = 0.022).
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the well-characterized pro-tumorigenic cytokines. 
It is upregulated in many cancers and is important 
for tumor cell proliferation, survival, differentiation, 
migration, invasion, metastasis and angiogenesis[9]. 
In the liver, IL-6 is involved in acute phase response, 
liver generation, and regulation of physiological 
and pathophysiological conditions. Similar to other 
cancers, IL-6 has been shown to be correlated with 
HCC development risk, advanced stage and poor 
survival[10-12]. In this study, serum IL-6 level showed 
borderline significance between patients with stage Ⅱ 
and Ⅳ disease, most likely due to the small number of 
patients with stage II disease (n = 4).
A history of pre-RT treatment was associated with 
a difference in baseline serum IL-6 level. Most of the 
treatment-non-naïve patients underwent TACE, and 
previous studies have demonstrated that serum IL-6 
level increases after TACE and is correlated with post-
TACE inflammation[13,14]. In these studies, the increase 
of serum IL-6 level occurred within several days after 
TACE and was attributed to a protective function of 
IL-6 against acute liver injury. In this study, the time 
interval between the last TACE and the start of RT 
was median 1.5 mo (range, 0.2-17.5 mo) and the 
Table 3  Univariate and multivariate analyses of clinical factors or cytokines for failure-free survival - infield failure-free survival
Univariate Multivariate
P  value RR (95%CI) P  value RR (95%CI)
Sex 0.001 10.262 (2.479-42.481) < 0.001   47.505 (7.384-305.601)
Age 0.198 0.968 (0.921-1.017)
Stage 0.082 2.106 (0.911-4.871)
BCLC 0.441 1.257 (0.702-2.250)
Size 0.903 1.007 (0.904-1.121)
PVT 0.247 1.741 (0.681-4.452)
LN metastasis 0.408 1.867 (0.425-8.191)
Multiplicity 0.944 1.033 (0.412-2.591)
AFP 0.653 0.999 (0.996-1.002)
PIVKA-II 0.889 0.996 (0.947-1.048)
Pre-RT treatment 0.290 1.627 (0.660-4.013)
Baseline IL-1 0.895 0.997 (0.955-1.041)
Baseline IL-6 0.000 1.011 (1.005-1.018) < 0.001 1.019 (1.011-1.028)
Baseline IL-8 0.985 1.000 (0.997-1.003)
Baseline IL-10 0.437 1.060 (0.915-1.227)
Baseline IL-12 0.903 0.996 (0.938-1.059)
Baseline TNF-α 0.864 0.993 (0.918-1.074)
Age, size, AFP, PIVKA-II, and baseline cytokine levels were analyzed as continuous variables using the Cox hazard ratio model. BCLC: Barcelona 
Clinic Liver Cancer; PVT: Portal vein thrombosis; LN: Lymph node; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: 
Radiotherapy; IL: Interleukin; TNF: Tumor necrosis factor.
Table 4  Univariate and multivariate analyses of clinical factors or cytokines for failure-free survival - outfield-intrahepatic failure-
free survival
Univariate Multivariate
P  value RR (95%CI) P  value RR (95%CI)
Sex 0.387 1.539 (0.579-4.086)
Age 0.834 0.996 (0.959-1.035)
Stage 0.601 0.834 (0.423-1.646)
BCLC 0.383 1.210 (0.788-1.859)
Size 0.534 0.974 (0.898-1.058)
PVT 0.326 1.433 (0.699-2.940)
LN metastasis 0.387 0.530 (0.126-2.230)
Multiplicity 0.303 1.464 (0.709-3.021)
AFP 0.649 1.000 (0.999-1.002)
PIVKA-II 0.920 1.002 (0.963-1.043)
Pre-RT treatment 0.745 1.126 (0.550-2.307)
Baseline IL-1 0.573 1.015 (0.964-1.069)
Baseline IL-6 0.271 0.950 (0.985-1.004)
Baseline IL-8 0.942 1.000 (0.998-1.002)
Baseline IL-10 0.026 0.830 (0.705-0.978) 0.026 0.830 (0.705-0.978)
Baseline IL-12 0.197 0.959 (0.901-1.022)
Baseline TNF-α 0.240 0.951 (0.876-1.034)
Age, size, AFP, PIVKA-II, and baseline cytokine levels were analyzed as continuous variables using the Cox hazard ratio model. BCLC: Barcelona 
Clinic Liver Cancer; PVT: Portal vein thrombosis; LN: Lymph node; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: 
Radiotherapy; IL: Interleukin; TNF: Tumor necrosis factor.
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baseline serum level was not correlated with the time 
interval. Therefore, the elevated serum IL-6 level in 
treatment-non-naïve patients of our study cannot 
be explained only by a pre-RT history of TACE. After 
TACE, TACE-induced hepatic tissue injuries around the 
tumor provoke an inflammatory response and alter 
the immune system. These inflammatory cytokine 
responses, including IL-6, may also induce tumor 
recurrence or progression after TACE. 
Among serum cytokines, only baseline serum IL-6 
was a significant factor for treatment failure in the 
RT field in this study. The effect of serum IL-6 on RT 
and chemoradiotherapy (CRT) response has been 
reported in many cancers, including lung, prostate, 
esophagus, stomach, pancreas, and head and neck 
cancers[15-17]. In previous reports, an elevated serum 
IL-6 level before RT/CRT was associated with poor 
treatment outcome. A high serum IL-6 level is known 
to correlate with tumor aggressiveness and associated 
tumor factors that affect treatment outcome, such 
as large size and advanced stage. However, there 
have been few studies on the effect of serum IL-6 on 
RT response in HCC. Jang et al[11] reported that IL-6 
was a strong inflammatory indicator for predicting 
the outcome in patients with HCC who received loco-
regional therapy (mainly TACE). RT was considered in 
patients with portal vein thrombosis or extrahepatic 
metastasis, and only 13 patients received RT after 
TACE. A higher IL-6 level was correlated with shorter 
survival. Chen et al[18] investigated the role of IL-6 in 
the radiation response of liver tumors. IL-6 expression 
was positively linked to radiation resistance in both in 
vivo and in vitro experiments. The authors suggested 
that concurrent treatment with IL-6 inhibitors could 
be a potential therapeutic strategy for increasing the 
radiation response of tumors.
In a previous report, we described the results of 
hepatic arterial concurrent chemoradiotherapy (CCRT) 
for advanced HCC and found that pre-CCRT treatment 
history was a predictive risk factor for treatment failure, 
particularly infield failure[19]. Based on the results of 
the current study, this difference in treatment outcome 
might be explained by the fact that treatment-non-
naïve patients had higher baseline serum IL-6 levels 
than treatment-naïve patients. Although application of 
RT has increased in the treatment of HCC, RT continues 
to be used as either complementary or salvage treat-
ment after other treatment modalities such as TACE, 
radiofrequency ablation or surgery, rather than as a 
primary treatment. Therefore, assessment of baseline 
serum cytokine levels, particularly IL-6, could be helpful 
in predicting the treatment outcome in treatment-non-
naïve patients.
To determine a useful criterion for predicting 
treatment outcomes in clinics, we identified the pre-
dictive cut-off value of baseline serum IL-6 level by 
ROC curve analysis. And 9.7 pg/mL as cut-off value 
was useful to predict infield failure in this study. Further 
Table 6  Variation of serum cytokine levels before and after 
radiotherapy (mean ± SEM)
Before RT (pg/mL) After RT (pg/mL) P  value
IL-1   6.77 ± 1.18   9.13 ± 1.51 0.229
IL-6 31.63 ± 7.34 29.54 ± 6.60 0.794
IL-8 115.75 ± 19.84 159.73 ± 38.96 0.211
IL-10   4.19 ± 0.41   5.83 ± 0.46 0.002
IL-12   6.10 ± 1.01   4.10 ± 0.59 0.018
TNF-α   4.27 ± 0.79   3.33 ± 0.40 0.130
IL: Interleukin; TNF: Tumor necrosis factor; RT: Radiotherapy.
Table 5  Univariate and multivariate analyses of clinical factors or cytokines for failure-free survival - extrahepatic failure-free 
survival
Univariate Multivariate
P  value RR (95%CI) P  value RR (95%CI)
Sex 0.153 2.043 (0.768-5.438)
Age 0.502 0.987 (0.951-1.025)
Stage 0.196 1.562 (0.795-3.070)
BCLC 0.782 0.942 (0.615-1.441)
Size 0.830 1.010 (0.926-1.101)
PVT 0.988 0.994 (0.465-2.125)
LN metastasis 0.936 0.952 (0.289-3.141)
Multiplicity 0.622 1.197 (0.586-2.448)
AFP 0.034 1.001 (1.000-1.003) 0.034 1.001 (1.000-1.003)
PIVKA-II 0.449 1.016 (0.976-1.057)
Pre-RT treatment 0.878 1.057 (0.520-2.147)
Baseline IL-1 0.725 1.005 (0.977-1.034)
Baseline IL-6 0.529 1.002 (0.996-1.007)
Baseline IL-8 0.546 1.001 (0.999-1.003)
Baseline IL-10 0.309 1.062 (0.946-1.193)
Baseline IL-12 0.726 1.009 (0.962-1.058)
Baseline TNF-α 0.956 1.002 (0.942-1.066)
Age, size, AFP, PIVKA-II, and baseline cytokine levels were analyzed as continuous variables using the Cox hazard ratio model. BCLC: Barcelona 
Clinic Liver Cancer; PVT: Portal vein thrombosis; LN: Lymph node; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: 
Radiotherapy; IL: Interleukin; TNF: Tumor necrosis factor.
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study is needed to verify this cut-off value in many 
patients with HCC treated with RT.
In this study, lower serum IL-10 level was correlated 
with worse outfield-intrahepatic FFS. IL-10 is known 
as a pleiotropic cytokine with dual roles in the immune 
system, including immune-suppression and immune-
stimulation[20]. Many studies reported that serum IL-10 
levels were higher in cancer patients than in healthy 
cohorts and that a higher IL-10 level was associated 
with worse prognosis[21]. However, other contradictory 
reports showed that patients with IL-10-negative 
tumors showed poor prognosis[22,23]. The inhibition of 
inflammatory cytokines and the stimulation of cytotoxic 
T cells by IL-10 have been further studied for cancer 
treatment using recombinant IL-10[24].
After RT, serum levels of IL-10 increased while 
the levels of IL-12 decreased. Several studies de-
monstrated changes in cytokine expression resulting 
from treatment of HCC. Cytokine levels are altered 
after treatment regimens including surgery or TACE; 
however, the direction of the change has not always 
been consistent between studies[25,26]. Although 
the change in the serum IL-10 or IL-12 level was 
not significantly associated with treatment failure 
in this study, these findings indicate that local RT 
might produce a systemic effect. It has been reported 
that local RT triggers systemic effects through the 
recruitment of biological effectors outside the radiation 
field[27]. 
The small number of patients was a limitation of 
this study and this limitation could affect statistical 
significance. Further large scale studies are needed 
to confirm our finding and to examine how radiation 
affects serum cytokine levels in HCC. In addition, this 
study was performed only in patients treated with RT. 
Further studies to identify serum cytokine levels in 
patients with HCC treated with other various treatment 
modalities might also be useful.
In conclusion, the current findings suggest that 
an assessment of serum cytokines may be helpful 
for predicting treatment outcome after RT in patients 
with HCC. In addition to tumor marker AFP, cytokines 
seemed to be useful in predicting infield failure 
(IL-6) and outfield-intrahepatic failure (IL-10). Serum 
cytokines could be useful biomarkers for predicting RT 
outcome in HCC.
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